Telix Operating Cycle from 2010 to 2024

TLX Stock   15.76  0.16  1.03%   
Telix Pharmaceuticals Operating Cycle yearly trend continues to be fairly stable with very little volatility. Operating Cycle will likely drop to 77.13 in 2024. During the period from 2010 to 2024, Telix Pharmaceuticals Operating Cycle regression line of annual values had r-squared of  0.12 and arithmetic mean of  274.73. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
81.18444737
Current Value
77.13
Quarterly Volatility
528.77460404
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Telix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telix Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 1.1 M, Depreciation And Amortization of 7.1 M or Interest Expense of 7.1 M, as well as many indicators such as Price To Sales Ratio of 0.41, Days Sales Outstanding of 45.23 or Average Payables of 1.8 M. Telix financial statements analysis is a perfect complement when working with Telix Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Telix Pharmaceuticals Correlation against competitors.

Latest Telix Pharmaceuticals' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Telix Pharmaceuticals Limited over the last few years. It is Telix Pharmaceuticals' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Telix Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

Telix Operating Cycle Regression Statistics

Arithmetic Mean274.73
Geometric Mean112.66
Coefficient Of Variation192.47
Mean Deviation329.82
Median82.50
Standard Deviation528.77
Sample Variance279,603
Range1.9K
R-Value0.35
Mean Square Error264,820
R-Squared0.12
Significance0.20
Slope41.05
Total Sum of Squares3.9M

Telix Operating Cycle History

2024 77.13
2023 81.18
2022 142.35
2021 1941.97
2020 1081.17
2019 112.05
2018 128.49

About Telix Pharmaceuticals Financial Statements

Telix Pharmaceuticals investors use historical fundamental indicators, such as Telix Pharmaceuticals' Operating Cycle, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Telix Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cycle 81.18  77.13 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.